NCT01719926已完成1 期
Phase I Study Evaluating Indomethacin in Combination With Platinum-based Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- UMC Utrecht
- 入组人数
- 13
- 试验地点
- 4
- 主要终点
- Number of dose limiting toxicities at each dosage cohort
研究概览
简要总结
Mesenchymal stem cells (MSCs) are present in the circulation of cancer patients, and are recruited to the stroma of both the primary tumor and metastasis. Recent preclinical research has shown that in response to platinum-based chemotherapy, MSCs secrete two specific platinum-induced fatty acids (PIFAs) which induce resistance to a broad spectrum of chemotherapies. The secreted PIFAs are the fatty acid oxo-heptadecatetraenoic acid (KHT) and the omega-3 fatty acid hexadecatetraenoic acid (16:4). These PIFAs are produced via the COX-1 pathway. COX inhibitors, including indomethacin. This phase 1 study explores the safety of combining indomethacin with platinum containing chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with a histological proven malignancy receiving cisplatin combined with gemcitabine or 5FU/capecitabine. (cisplatin dose range 60-80 mg/m2) (Arm I) or CAPOX (oxaliplatin, capecitabine) (Arm II) in a 21 day cycle.
- •Age ≥ 18 years
- •Platinum-based chemotherapy naïve for at least 6 months.
- •Subjects with at least one evaluable lesion.
- •WHO Performance Status of 0 or
- •Female participants should be of non-child bearing potential either physiologic or by using adequate contraception, have a negative serum pregnancy test, and refrain from breast feeding.
- •Written informed consent.
排除标准
- •Known or suspected allergy or hypersensitivity to indomethacin or any agent given in association with this trial, in particular subjects who have a history of severe hypersensitivity reactions to anti-emetics (5-HT3 antagonists, metoclopramide or corticosteroids) and acetylsalicylic acid or other prostaglandin synthetase inhibitors.
- •Symptomatic brain or meningeal tumors
- •Subjects with seizure disorder requiring medication (such as corticosteroids or anti-epileptics).
- •Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:
- •Uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen
- •Unstable angina pectoris
- •Symptomatic congestive heart failure NYHA class ≥ 3 (see appendix 13.6)
- •Myocardial infarction ≤ 6 months prior to randomization
- •Serious uncontrolled cardiac arrhythmia
- •Active peptic ulcer disease, gastritis, inflammatory bowel disease.
- •History of active gastrointestinal bleeding
- •History of cerebrovascular disease
- •Bleeding diathesis
- •Chronic renal disease defined as GFR (MDRD) <60 ml/min
- •Absolute Neutrophil Count (ANC) < 1.5 x 109/L (< 1500/mm3)
- •Platelets (PLT) < 100 x 109/L (< 100,000/mm3)
- •Hemoglobin (Hgb) < 6.0 mmol/l (patients may be transfused to achieve adequate Hb)
- •Partial thromboplastin time (PTT) > 1,5 x ULN
- •Serum bilirubin > 1.5 ULN
- •Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) > 3.0 x ULN (> 5 x ULN if liver metastases present)
- •Patients who are unable or unwilling to comply with the protocol
- •Chronic treatment with a corticosteroid agent (nebulized corticosteroids are allowed)
- •Patients who received radiation therapy within 4 weeks of the start of the study
- •Patients who received an experimental agent less than 4 weeks before start of the study.
- •Patients who used Omega-3/omega-6 containing products, including fish oil products less than 2 weeks before start of the study.
- •Chronic use of NSAID's and/or acetylsalicylic acid and/or other prostaglandin synthetase inhibitors.
- •Use of anticoagulant therapy
研究组 & 干预措施
Capecitabine/Oxaliplatin
Experimental
Patients receiving Capecitabine/Oxaliplatin chemotherapy
干预措施: Indomethacin (Drug)
Cisplatin + Xeloda(Capecitabine) or Gemcitabine
Experimental
Patients receiving Cisplatin regimen
干预措施: Indomethacin (Drug)
结局指标
主要结局
Number of dose limiting toxicities at each dosage cohort
时间窗: From first dose of indomethacin until 28 days after last dose of indomethacin
次要结局
- Pharmacodynamics(During first 2 cycles of 3 weeks each)
- Efficacy(From baseline to date of progressive disease according RECIST 1.1, approximately 9 to 18 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
1 期
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D MutationKRAS NP_004976.2:p.G12DMetastatic Pancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8NCT03608631M.D. Anderson Cancer Center28
Unknown
2 期
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host DiseaseChronic Graft Versus Host DiseaseNCT01526850Chinese Academy of Medical Sciences100
招募中
2 期
Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem CellsLupus NephritisLupus ErythematosusNCT03673748Red de Terapia Celular20
撤回
1 期
ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 SyndromePostviral SyndromeCovid19DyspneaNCT05116761Direct Biologics, LLC60
已完成
1 期
Treatment CLI Nonrevascularizable Lower Limb With Cell TherapyNonrevascularizable Critical Ischemia of the Lower LimbsNCT01824069Instituto de Investigación Hospital Universitario La Paz10